Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acolbifene - Endoceutics

Drug Profile

Acolbifene - Endoceutics

Alternative Names: Acolbifene hydrochloride; EM 652.HCl; EM-652; SCH 57068; SCH 57068.HCl

Latest Information Update: 11 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endoceutics
  • Developer Endoceutics; National Cancer Institute (USA)
  • Class Antineoplastics; Benzopyrans; Osteoporosis therapies; Phenyl ethers; Piperidines
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 11 Jul 2019 Phase III development for Breast cancer is ongoing in Canada (Endoceutics pipeline, July 2019)
  • 09 Oct 2015 No recent reports on development identified - Phase-II for Breast cancer (Prevention) in USA (PO)
  • 23 Jul 2015 Further phase III development for Breast cancer is pending as Endoceutics seeks a partner for out-licensing
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top